{"id":"perfusion-of-treatment-ocrelizumab","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Neurological disorders"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:01:32.207571","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CD20, ocrelizumab triggers the depletion of B cells, which are involved in the pathogenesis of multiple sclerosis and other autoimmune diseases. This depletion leads to a reduction in disease activity and symptoms. Ocrelizumab has been shown to be effective in treating relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.","oneSentence":"Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:14.039Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"},{"name":"Primary progressive multiple sclerosis"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT05758831","phase":"PHASE3","title":"RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.","status":"RECRUITING","sponsor":"Rennes University Hospital","startDate":"2023-06-01","conditions":"Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis","enrollment":386}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Perfusion of treatment Ocrelizumab","genericName":"Perfusion of treatment Ocrelizumab","companyName":"Rennes University Hospital","companyId":"rennes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}